Analysts Offer Insights on Healthcare Companies: Arrowhead Research (NASDAQ: ARWR), Corbus Pharmaceuticals (NASDAQ: CRBP) and Ariad (NASDAQ: ARIA)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Research (NASDAQ: ARWR), Corbus Pharmaceuticals (NASDAQ: CRBP) and Ariad (NASDAQ: ARIA).

Arrowhead Research (NASDAQ: ARWR)

In a report released today, Eun Yang from Jefferies reiterated a Hold rating on Arrowhead Research (NASDAQ: ARWR), with a price target of $2. The company’s shares opened today at $1.69, close to its 52-week low of $1.61.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 1.8% and a 49.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Arrowhead Research is Moderate Buy and the average price target is $2, representing a 18.3% upside.

In a report released today, Cantor Fitzgerald also downgraded the stock to Hold.
Corbus Pharmaceuticals (NASDAQ: CRBP)

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP). The company’s shares opened today at $7.90.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 5.9% and a 50.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $17.

Ariad (NASDAQ: ARIA)

In a report released today, Michael King from JMP Securities reiterated a Hold rating on Ariad (NASDAQ: ARIA). The company’s shares opened today at $13.86, close to its 52-week high of $14.42.

According to TipRanks.com, King is a 3-star analyst with an average return of 1.2% and a 46.1% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.

Ariad has an analyst consensus of Moderate Buy, with a price target consensus of $12.